Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGT-264 in advanced solid tumors
NCT05764915Phase 1Terminated
- Sponsor
- Regor Therapeutics
- Start
- Feb 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RGT-264 in solid tumor (advanced stage), sponsored by Regor Therapeutics. Primary endpoints: Dose-Limiting Toxicities and Adverse Events. Started Feb 2023; status: terminated.
02
Drugs
RGT-264
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05764915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05764915.